Alector drops 31% as Alzheimer's candidate fails in phase 2 trial

Jonathan Kitchen Alector ( NASDAQ: ALEC ) is down ~31% in after-hours trading Monday after releasing results from a phase 2 trial on its Alzheimer's asset AL002 that missed its primary endpoint. AL002 failed to slow Alzheimer’s clinical progression measured by the Clinical Dementia Rating.